A -- National Lung Screening Trial

The National Cancer Institute (NCI) intends to negotiate with the Screening Centers of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial for the National Lung Screening Trial (NLST). The PLCO Screening Centers include: the University of Pittsburgh Cancer Institute, N01-CN-25511; Georgetown University, N01-CN-25522; Henry Ford Hospital, N01-CN-25512; University of Minnesota, N01-CN-25513; University of Colorado Health Sciences Center, N01-CN-25514; Straub Pacific Health Research Institute; N01-CN-25515; Washington University, N01-CN-25516; Marshfield Medical Research and Education Foundation, N01-CN-25518; University of Utah, N01-CN-25524; and University of Alabama at Birmingham, N01-CN-75022. The National Lung Screening Trial is a special study within the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial to investigate lung cancer detection rates for single view chest x-ray (CXR) and spiral CT (SCT) in a population at high risk for development of the disease. This solicitation is for the recruitment of 36,000 smokers and former smokers over two years to an initial screen and two more annual screens. For the coordination of the National Lung Screening Trial, NCI intends to negotiate with Westat, Inc., N01-CN-25476. Study coordination includes: meeting with the NCI personnel to review progress and resolve problems; monitor progress and protocol adherence at screening centers and prepare monthly status reports; coordinate conference calls and provide minutes; maintain and update study-specific information and NLST Manual of Operations and Procedures (MOOP). Authority: 41 U.S.C. 253(c)(1), as set forth in FAR 6.302-1. See Numbered Note 22.